Incyte price to book ratio INCY
Market value divided by the book value of the company's net assets, since 2016.
- Today, Nov 3, 2026
- 3.8×
- 10-year median
- 5.1×
- Against its 10-year history
- 23rd
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 2.2× to 67.4×
- Peer median
- 5.9×
Incyte's price to book ratio is 3.8× as of Nov 3, 2026.
That is below its ten-year median of 5.1×, lower than on 77% of days in the last ten years.
Over that time it ranged from 2.2× in May 2024 to 67.4× in Mar 2017.
The median for 10 biotech stocks of a similar size is 5.9×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 3.8× | 3.4× | 4.6× |
| 2025 | 4.2× | 3.1× | 4.5× |
| 2024 | 4.2× | 2.2× | 5.1× |
| 2023 | 2.9× | 2.4× | 4.5× |
| 2022 | 4.2× | 3.6× | 5.3× |
| 2021 | 5.1× | 4.5× | 9.0× |
| 2020 | 8.0× | 5.6× | 11.9× |
| 2019 | 7.9× | 7.0× | 9.8× |
| 2018 | 7.4× | 6.9× | 12.2× |
| 2017 | 11.4× | 11.4× | 67.4× |
| 2016 | 51.1× | 44.6× | 199× |
Against its peers
Companies in Biotechnology nearest Incyte's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| INCYIncyte | 3.8× |
| UTHRUnited Therapeutics | 4.0× |
| ALNYAlnylam Pharmaceuticals | 15.7× |
| EXELExelixis | 9.4× |
| NBIXNeurocrine Biosciences | 4.0× |
| HALOHalozyme Therapeutics | 102× |
| ONCBeOne Medicines | 7.8× |
| TECHBIO-TECHNE | 5.4× |
| RGENRepligen | 4.6× |
| KRYSKrystal Biotech | 6.4× |
| REGNRegeneron Pharmaceuticals | 3.2× |
| Peer median | 5.9× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Incyte
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.